$QURE AMT-130, uniQure’s gene therapy for Huntington’s, is now under review in the US and UK. The results today are encouraging, and it made me want to look further ahead.
My new piece treats it as a starting point rather than a verdict. Recent research shows the disease advancing inside each vulnerable neuron over decades before a tipping point, which strengthens the case for intervening earlier. Laboratory tools are improving quickly, but clinical evidence still runs on human time.
Written for families and readers who want an honest account of where the science stands and where it could go:
clearpath100.substack.com/p/…

ALT I wrote about AMT-130, uniQure’s gene therapy for Huntington’s, not as a verdict but as a starting point. Inside every vulnerable neuron the disease runs like a clock: decades of quiet, then a tipping point. The science of the next decade is about finding the window. Hopeful, honest about the limits, and written for the families for whom ten years is not an abstraction.
31
2,210
$MRNA Moderna’s investigational cancer vaccine raises a bigger AI question: when generating ideas gets cheaper, who gets paid to prove they work?
The full deep dive can be found here:
clearpath100.substack.com/p/…
2
318
$NVDA keeps 75c of gross profit on every $ of sales.
$CRWV which rents out those chips, posted an operating loss after $1.39 bln of depreciation in one quarter.
Same machines. Very different math. 👇
clearpath100.substack.com/p/…
281
$NBIS Nebius raised its listed non-preemptible H100 GPU rental rate by 16.9% and H200 by 20% on 1 October. How can cheaper intelligence build a more expensive world?
My essay follows the money and the machinery:
clearpath100.substack.com/p/…
1
4,949
$TWST A year ago, AI-designed antibodies worked about 1 time in 1,000. Now it's closer to 1 in 6. Every design still has to be made and tested, so the scarce input is now the experiment.
Free link to the full article here:
clearpath100.substack.com/p/……




